Shanghai Bio‑heart Biological Technology Co., Ltd. (HKG: 2185) announced a strategic cooperation agreement with Shanghai Shenqi Medical Technology Co., Ltd. (“Shenqi Medical”) for the commercial promotion of the BioHeart Bioabsorbable Rapamycin‑Eluting Coronary Stent System (the “BioHeart Stent”), with both parties committing to jointly advance the commercialisation and clinical application of the independently developed device.
Partnership Snapshot
| Item | Detail |
|---|---|
| Parties | Shanghai Bio‑heart Biological Technology Co., Ltd. (HKG: 2185) and Shanghai Shenqi Medical Technology Co., Ltd. (Shenqi Medical) |
| Agreement Type | Strategic cooperation agreement — commercial promotion |
| Product | BioHeart Bioabsorbable Rapamycin‑Eluting Coronary Stent System |
| Product Status | New‑generation bioabsorbable stent independently developed by Bio‑heart; registration/approval status not specified in announcement |
| Collaboration Scope | Market channel development and academic promotion, leveraging each party’s respective resource advantages |
| Announcement Date | 15 Sep 2026 |
| Financial Terms | Not disclosed |
Device Profile & Technology
- Platform: A new‑generation bioabsorbable rapamycin‑eluting coronary stent system, independently developed by Bio‑heart.
- Strut Design: Adopts an ultra‑thin strut design, aimed at improved deliverability and vessel compatibility versus conventional thick‑strut scaffolds.
- Bioabsorption: The stent can be gradually degraded and absorbed in vivo, realizing the treatment philosophy of “interventional treatment without implantation” — leaving no permanent metallic implant in the vessel after scaffold function is complete.
- Drug Coating: A poly‑D,L‑lactic acid (PDLLA) sustained‑release coating loaded with sirolimus (rapamycin) effectively inhibits neointimal hyperplasia through sustained drug release and supports long‑term luminal stability.
- Clinical Rationale: Bioabsorbable scaffolds are designed to restore natural vessel vasomotion and eliminate the long‑term foreign‑body presence associated with permanent drug‑eluting stents, addressing a recognized limitation in percutaneous coronary intervention (PCI).
Market Impact & Outlook
- Commercialization Acceleration: The agreement pairs Bio‑heart’s product ownership with Shenqi Medical’s promotion resources, targeting faster market channel development and broader hospital access for the BioHeart Stent across China’s interventional cardiology market.
- Academic Promotion Focus: Joint academic promotion reflects the evidence‑driven adoption model for innovative devices in China, where clinical consensus and physician education are critical to uptake of next‑generation technologies.
- China PCI Landscape: Coronary intervention volumes in China continue to expand with an aging population and rising cardiovascular disease burden, while centralized procurement pressures on conventional drug‑eluting stents have intensified industry focus on differentiated, premium‑segment devices such as bioabsorbable scaffolds.
- Pipeline Positioning: Commercial execution of the BioHeart Stent strengthens Bio‑heart’s profile as a developer of next‑generation cardiovascular implant technologies beyond its established structural heart portfolio.
- Terms: Revenue‑sharing arrangements, sales targets and rollout timelines were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the strategic cooperation between Bio‑heart and Shenqi Medical and the commercialization of the BioHeart Bioabsorbable Rapamycin‑Eluting Coronary Stent System, including expectations around market access and clinical adoption. Actual results may differ materially due to risks including regulatory approvals, commercialization execution, competitive dynamics, and changes in procurement or reimbursement policies.-Fineline Info & Tech
